Insights from 2023 SABCS


 

SABCS 2023 Insights: "DEBBRAH Study - Trastuzumab Deruxtecan in Patients With HER2+/HER2-Low Advanced BC and Pathologically Confirmed Leptomeningeal Carcinomatosis"

177 views
December 18, 2023
Comments 0
Login to view comments. Click here to Login